Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Apostolides

Plastic Surgery San Diego, CA Medical Doctor

NPI 1659427912 CMS profile 211218

1322 Scott St, Suite 102, San Diego, CA 92106

Open in the dashboard

General payments

$460,434

370 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Apostolides of San Diego, CA is reported in the CMS Open Payments database as having received $460,434 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125,870 77
2024 General $55,524 39
2023 General $30,679 32
2022 General $47,896 38
2021 General $45,044 53
2020 General $33,333 45
2019 General $122,087 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Apostolides
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to John Apostolides were reported at $125,870. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year John Apostolides Plastic Surgery median Middle half National median
2019 $122,087 $371 $122–$1,483 $163
2020 $33,333 $158 $52–$438 $114
2021 $45,044 $249 $87–$752 $132
2022 $47,896 $274 $102–$793 $149
2023 $30,679 $299 $113–$891 $160
2024 $55,524 $361 $124–$1,062 $164
2025 $125,870 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $210,912 143 payments
  2. KCI USA, Inc $132,639 120 payments
  3. Allergan Inc. $107,733 97 payments
  4. Solventum Corporation $5,973 3 payments
  5. Heron Therapeutics, Inc. $3,075 4 payments
  6. Innovation Technologies Inc $59 1 payment
  7. Sientra, Inc. $24 1 payment
  8. TELA Bio, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $216,436 56 payments
  2. Consulting Fee $188,294 100 payments
  3. Travel and Lodging $49,170 101 payments
  4. Food and Beverage $5,855 110 payments
  5. Education $680 3 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $168,167 107 payments
  2. PREVENA Non-Covered $79,072 56 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $66,390 61 payments
  4. ALLODERM $41,513 33 payments
  5. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $23,132 7 payments
  6. PREVENA Negative Pressure Systems & Dressings $21,686 23 payments
  7. NATRELLE $20,457 24 payments
  8. REVOLVE $11,997 19 payments
  9. PREVENA RESTOR BELLAFORM $11,238 9 payments
  10. STRATTICE $10,173 10 payments
  11. Other $63,361 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

194

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,053

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

22.2%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 62 $738
Celecoxib Generic 31 $571
Ondansetron Odt Ondansetron Brand 32 $439
Oxycodone Hcl Generic 58 $275
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$172,909

Medicare's payments for the services billed

Medicare patients

100

Average age 71

Services billed

627

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 51%
Arthritis 48%
Osteoporosis 29%
Depression 20%
Diabetes 13%
Ischemic heart disease 11%
COPD 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record